In an HIV‑infected patient, how do CD4 cell count thresholds determine which opportunistic infections require prophylaxis and what specific preventive measures should be used?

CD4 Count Thresholds and Opportunistic Infection Prophylaxis in HIV

Primary Prophylaxis Initiation Based on CD4 Count

All HIV-infected adults must receive trimethoprim-sulfamethoxazole (TMP-SMX) double-strength (800/160 mg) once daily when CD4 count falls below 200 cells/µL, which simultaneously prevents Pneumocystis jirovecii pneumonia (PCP), toxoplasmosis in seropositive patients, and common bacterial respiratory infections. 1

PCP Prophylaxis (CD4 <200 cells/µL)

• Start TMP-SMX immediately when CD4 <200 cells/µL, regardless of symptoms, viral load, or antiretroviral therapy status 1
• Also initiate prophylaxis at any CD4 count if the patient has oropharyngeal candidiasis or unexplained fever >100°F for ≥2 weeks 1
• Consider starting prophylaxis when CD4 is 200-250 cells/µL if monitoring every 3 months is not feasible, to avoid missing the threshold 1
• A **CD4 percentage <14%** is an alternative threshold that should trigger prophylaxis even if absolute count is >200 cells/µL 1, 2

Preferred regimen: TMP-SMX double-strength tablet (160 mg TMP/800 mg SMX) once daily 1

Alternative dosing schedules:

• Single-strength tablet once daily (better tolerated, equally effective) 1
• Double-strength tablet three times weekly (Monday/Wednesday/Friday) 1

Toxoplasmosis Prophylaxis (CD4 <100 cells/µL)

• Initiate prophylaxis when CD4 <100 cells/µL in Toxoplasma-IgG-positive patients 1
• Daily TMP-SMX double-strength alone provides adequate toxoplasmosis coverage—no additional agent is needed 1, 3
• Test Toxoplasma IgG serology immediately if status is unknown; if positive and CD4 <100 cells/µL, continue TMP-SMX alone 1, 3
• Retest seronegative patients when CD4 falls below 100 cells/µL to detect seroconversion 1, 3

Mycobacterium avium Complex (MAC) Prophylaxis (CD4 <50 cells/µL)

• Begin MAC prophylaxis when CD4 <50 cells/µL 1, 3

Preferred regimen: Azithromycin 1200 mg once weekly (better adherence, fewer drug interactions) 1, 3, 4

Alternative regimens:

• Clarithromycin 500 mg twice daily (equally effective but more protease inhibitor interactions) 1, 3, 4
• Rifabutin 300 mg daily (second-line; requires dose adjustments with most antiretrovirals and exclusion of active tuberculosis) 1, 3, 4

Critical warning: Never combine clarithromycin with rifabutin—this increases adverse effects without improving efficacy 1, 3, 4

Alternative Regimens for TMP-SMX Intolerance

Up to 70% of patients who develop non-life-threatening TMP-SMX reactions can tolerate rechallenge using gradual dose escalation (desensitization). 1, 3, 5

For PCP-Only Coverage:

• Dapsone 100 mg daily (no toxoplasmosis protection) 1, 3
• Atovaquone 1500 mg daily (no toxoplasmosis protection; substantially more expensive) 1, 3
• Aerosolized pentamidine 300 mg monthly via Respirgard II nebulizer (least preferred; no systemic or toxoplasmosis coverage) 1, 3

For Combined PCP and Toxoplasmosis Coverage:

• Dapsone 50 mg daily + pyrimethamine 50 mg weekly + leucovorin 25 mg weekly (for TMP-SMX-intolerant, Toxoplasma-IgG-positive patients with CD4 <100 cells/µL) 1, 3, 4

Never use aerosolized pentamidine as sole prophylaxis when CD4 <100 cells/µL—it does not protect against toxoplasmosis 1, 3, 4

Discontinuation of Prophylaxis After Immune Reconstitution

Prophylaxis may be safely stopped only after sustained CD4 recovery on antiretroviral therapy for ≥3 months with virologic suppression. 1, 3, 4, 5

Infection	Discontinuation Threshold	Required ART Duration
PCP	CD4 >200 cells/µL	≥3 months sustained
Toxoplasmosis	CD4 >200 cells/µL	≥3 months sustained
MAC	CD4 >100 cells/µL	≥3 months sustained

1, 3, 4, 5

Restart criteria:

• Reinitiate PCP and toxoplasmosis prophylaxis if CD4 falls below 200 cells/µL 1, 3, 4, 5
• Reinitiate MAC prophylaxis if CD4 falls below 50-100 cells/µL 1, 3, 4
• Never discontinue based on a single CD4 measurement—sustained elevation for the full 3-month period is mandatory 1, 3, 4, 5

Antiretroviral Therapy Initiation

Start integrase-inhibitor-based ART immediately upon HIV diagnosis, even before genotype results are available. 3

Preferred first-line regimens:

• Bictegravir/tenofovir alafenamide/emtricitabine 3
• Dolutegravir + tenofovir + emtricitabine 3

For most opportunistic infections, start ART within 2 weeks of OI diagnosis. 3

Drug Interaction Considerations

• Azithromycin is preferred over clarithromycin for MAC prophylaxis due to fewer interactions with protease inhibitors 3, 4, 5
• Rifabutin requires dose adjustments when co-administered with most protease inhibitors and NNRTIs 1, 3, 4
• TMP-SMX has minimal interactions with ART, making it compatible with all first-line regimens 3

Special Populations

Pregnant Women

• Administer TMP-SMX using the same CD4-based criteria as non-pregnant adults 1, 4
• During the first trimester, aerosolized pentamidine may be substituted due to theoretical teratogenicity concerns (weaker recommendation) 1, 4

Infants and Children

• HIV-exposed infants should start TMP-SMX at 4-6 weeks of age and continue through the first year of life, regardless of HIV infection status 1, 4, 5
• HIV-infected children should continue prophylaxis after the first year based on age-specific CD4 thresholds 1, 4, 5

Critical Clinical Pitfalls to Avoid

• Never delay PCP prophylaxis while awaiting CD4 results in patients with oropharyngeal candidiasis or a prior AIDS-defining illness 3, 4, 5
• Never abandon TMP-SMX for minor adverse reactions without attempting desensitization or dose modification 1, 3, 5
• Never use aerosolized pentamidine as first-line prophylaxis when TMP-SMX is tolerated—it lacks systemic coverage and does not prevent toxoplasmosis 1, 3, 4
• Never combine clarithromycin with rifabutin for MAC prophylaxis 1, 3, 4
• Never discontinue prophylaxis prematurely—ensure sustained CD4 elevation for the full 3-month period 1, 3, 4, 5
• Exclude active tuberculosis before starting rifabutin to avoid inducing rifampin resistance 1, 3, 4